Nicolas Goossens

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6557963/publications.pdf

Version: 2024-02-01

72 papers	3,731 citations	201674 27 h-index	133252 59 g-index
78 all docs	78 docs citations	78 times ranked	6800 citing authors

#	Article	IF	Citations
1	Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. Journal of Hepatology, 2018, 68, 526-549.	3.7	506
2	Cancer biomarker discovery and validation. Translational Cancer Research, 2015, 4, 256-269.	1.0	354
3	A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. Journal of Hepatology, 2018, 69, 385-395.	3.7	330
4	Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nature Immunology, 2015, 16, 1235-1244.	14.5	278
5	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell, 2016, 30, 879-890.	16.8	172
6	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology, 2012, 55, 384-394.	7.3	138
7	Hepatitis C virus-induced hepatocellular carcinoma. Clinical and Molecular Hepatology, 2015, 21, 105.	8.9	127
8	Cost-Effectiveness of Risk Scoreâ€“Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clinical and Translational Gastroenterology, 2017, 8, e101.	2.5	124
9	Is genotype 3 of the hepatitis C virus the new villain?. Hepatology, 2014, 59, 2403-2412.	7.3	116
10	Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nature Communications, 2018, 9, 4962.	12.8	111
11	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut, 2016, 65, 1754-1764.	12.1	108
12	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). Journal of Hepatology, 2021, 75, 610-622.	3.7	96
13	Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepatic Oncology, 2015, 2, 371-379.	4.2	95
14	Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Journal of Hepatology, 2020, 73, 533-539.	3.7	94
15	Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver International, 2016, 36, 108-118.	3.9	93
16	The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy. Scientific Reports, 2016, 6, 39342.	3.3	77
17	Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases. Experimental and Molecular Medicine, 2017, 49, e396-e396.	7.7	61
18	Using Big Data to Discover Diagnostics and Therapeutics forÂGastrointestinal and Liver Diseases. Gastroenterology, 2017, 152, 53-67.e3.	1.3	61

#	Article	IF	Citations
19	Hepatic cell proliferation plays a pivotal role in the prognosis of alcoholic hepatitis. Journal of Hepatology, 2015, 63, 609-621.	3.7	59
20	NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Reports, 2021, 3, 100231.	4.9	54
21	Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. Clinical Gastroenterology and Hepatology, 2016, 14, 1619-1628.	4.4	47
22	Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients WithÂSevere Alcoholic Hepatitis. Gastroenterology, 2018, 154, 965-975.	1.3	41
23	Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance. Nature Communications, 2017, 8, 1820.	12.8	40
24	Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Science Translational Medicine, 2022, 14, .	12.4	40
25	Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. Journal of Advanced Research, 2017, 8, 149-159.	9.5	39
26	Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. Scientific Reports, 2017, 7, 42563.	3.3	29
27	Use of big data in drug development for precision medicine. Expert Review of Precision Medicine and Drug Development, 2016, 1, 245-253.	0.7	28
28	Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signature. Hepatology, 2017, 66, 1344-1346.	7.3	28
29	Activation of the oncogenic miRâ€21â€5p promotes HCV replication and steatosis induced by the viral core 3a protein. Liver International, 2019, 39, 1226-1236.	3.9	24
30	The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis C. Clinics in Liver Disease, 2014, 18, 147-156.	2.1	23
31	Cardiovascular Manifestations of Hepatitis C Virus. Clinics in Liver Disease, 2017, 21, 465-473.	2.1	23
32	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. Nature Communications, 2021, 12, 5525.	12.8	21
33	Tailored Algorithms for Hepatocellular Carcinoma Surveillance: Is One-Size-Fits-All Strategy Outdated?. Current Hepatology Reports, 2017, 16, 64-71.	0.9	17
34	Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection. Reviews on Recent Clinical Trials, 2015, 9, 204-209.	0.8	17
35	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. Gastroenterology, 2022, 162, 1210-1225.	1.3	17
36	Drug Pricing Evolution in Hepatitis C. PLoS ONE, 2016, 11, e0157098.	2.5	16

#	Article	IF	Citations
37	Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease. World Journal of Hepatology, 2018, 10, 73-81.	2.0	14
38	Severe immune-mediated drug-induced liver injury linked to ibandronate: A case report. Journal of Hepatology, 2013, 59, 1139-1142.	3.7	13
39	Is Hepatocellular Cancer the Same Disease in Alcoholic andÂNonalcoholic Fatty Liver Diseases?. Gastroenterology, 2016, 150, 1710-1717.	1.3	13
40	Molecular prognostic prediction in liver cirrhosis. World Journal of Gastroenterology, 2015, 21, 10262.	3.3	12
41	Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease. Nutrients, 2017, 9, 1077.	4.1	12
42	Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 317-325.	3.3	12
43	Gene signatureâ€MELD score and alcohol relapse determine longâ€term prognosis of patients with severe alcoholic hepatitis. Liver International, 2020, 40, 565-570.	3.9	12
44	Nonalcoholic fatty liver disease burden â€“ Switzerland 2018â€“2030. Swiss Medical Weekly, 2019, 149, w20152.	1.6	12
45	Use of glasgow-blatchford bleeding score reduces hospital stay duration and costs for patients with low-risk upper GI bleeding. Endoscopy International Open, 2014, 02, E74-E79.	1.8	11
46	A return to harmful alcohol consumption impacts on portal hemodynamic changes following alcoholic hepatitis. European Journal of Gastroenterology and Hepatology, 2018, 30, 967-974.	1.6	11
47	Endovascular Treatment of Arterial Complications After Liver Transplantation: Long-Term Follow-Up Evaluated on Doppler Ultrasound and Magnetic Resonance Cholangiopancreatography. CardioVascular and Interventional Radiology, 2019, 42, 381-388.	2.0	11
48	Recent advances in gastrointestinal cancers. World Journal of Gastroenterology, 2021, 27, 4493-4503.	3.3	11
49	DOME/GALT type adenocarcimoma of the colon: a case report, literature review and a unified phenotypic categorization. Diagnostic Pathology, 2015, 10, 92.	2.0	8
50	Repositioning of a novel GABA-B receptor agonist, AZD3355 (Lesogaberan), for the treatment of non-alcoholic steatohepatitis. Scientific Reports, 2021, 11, 20827.	3.3	7
51	Origin and interpretation of cancer transcriptome profiling: the essential role of the stroma in determining prognosis and drug resistance. EMBO Molecular Medicine, 2015, 7, 1385-1387.	6.9	6
52	Novel substituted aminothiazoles as potent and selective anti-hepatocellular carcinoma agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5819-5824.	2.2	6
53	Peribiliary Gland Dilatation in Cirrhosis: Relationship with Liver Failure and Stem Cell/Proliferation Markers. Digestive Diseases and Sciences, 2017, 62, 699-707.	2.3	6
54	Tolerogenic properties of liver macrophages in nonâ€alcoholic steatohepatitis. Liver International, 2020, 40, 609-621.	3.9	6

#	Article	IF	Citations
55	Clinical Presentation and Gene Expression of Acute Alcoholâ€Induced Microvesicular Steatosis Mimicking Alcoholic Hepatitis. Hepatology Communications, 2021, 5, 618-628.	4.3	6
56	Impact of Maternal Obesity on Liver Disease in the Offspring: A Comprehensive Transcriptomic Analysis and Confirmation of Results in a Murine Model. Biomedicines, 2022, 10, 294.	3.2	6
57	Digital clubbing in association with hepatopulmonary syndrome. Hepatology, 2011, 53, 365-366.	7.3	5
58	Liver volume is a prognostic indicator for clinical outcome of patients with alcoholic hepatitis. Abdominal Radiology, 2017, 42, 460-467.	2.1	5
59	Personalized management of hepatocellular carcinoma based on molecular information: Future prospects. Clinical Liver Disease, 2015, 5, 132-135.	2.1	4
60	Effect of hepatitis B virus on steatosis in hepatitis C virus coâ€infected subjects: A multiâ€centre study and systematic review. Journal of Viral Hepatitis, 2018, 25, 920-929.	2.0	3
61	Management of hepatocellular carcinoma: SASL expert opinion statement. Swiss Medical Weekly, 2020, 150, w20296.	1.6	3
62	NAFLD is a rising cause of HCC in women in a prospective populational cohort spanning 24 years (1990â€“2014). Journal of Hepatology, 2020, 73, S160-S161.	3.7	1
63	Autologous hematopoietic stem cell transplantation into the liver: impact on hepatic macrophagic expansion and gene expression. Journal of Hepatology, 2017, 66, S351.	3.7	0
64	Mortality in Bariatric Surgery. , 2017, , 207-216.		0
65	THU-203-Hepatitis D infection and risk of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Journal of Hepatology, 2019, 70, e252-e253.	3.7	0
66	A human liver cell-based system modeling a clinical prognostic liver signature combined with single cell RNA-seq for discovery of novel liver disease therapeutics. Journal of Hepatology, 2020, 73, S28-S29.	3.7	0
67	Reply to: â€œCirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinomaâ€. Journal of Hepatology, 2020, 73, 1585-1586.	3.7	0
68	Management of Acute Wilsonian Hepatitis with Severe Hemolysis: A Successful Combination of Chelation and MARS Dialysis. Case Reports in Hepatology, 2021, 2021, 1-6.	0.7	0
69	COVID-19-related abdominal pain is associated with elevated liver transaminases, which could predict poor clinical outcomes. British Journal of Surgery, 2021, 108, .	0.3	0
70	Use of induction therapy in pediatric heart transplant recipients in Switzerland â€“ Analysis of the Swiss national database. Transplant Immunology, 2021, 68, 101443.	1.2	0
71	Non-invasive diagnosis of liver steatosis: ready for primetime?. Swiss Medical Weekly, 2019, 149, w20108.	1.6	0
72	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. The Cochrane Library, 2021, 2021, .	2.8	0